1.Enhancement of urinary elimination of 3-bromobenzanthrone metabolites by oral supplementation of ascorbic acid in guinea pigs.
Ravindra P SINGH ; Raj KHANNA ; Subhash K KHANNA ; Mukul DAS
Biomedical and Environmental Sciences 2004;17(4):390-396
OBJECTIVE3-Bromobenzanthrone (3-BBA), an anthraquinone intermediate dye, is extensively used in textile industry. Since, our prior studies have shown that 3-BBA caused significant depletion of ascorbic acid (AsA) levels, the effect of exogenous supplementation of AsA on the urinary elimination of 3-BBA metabolites was investigated.
METHODGuinea pigs were treated with single oral dose of 3-BBA (50 mg/kg b. wt.) in groundnut oil while another group was treated with single oral dose of 3-BBA (50 mg/kg b. wt.) along with 3 day prior and post oral supplementation of AsA. Control groups were either treated with groundnut oil or AsA alone. Urine from individual animals was collected, extracted and analysed on HPTLC.
RESULTSThe highest elimination of 3-BBA (75 microg) was found to be in 0-24 h urine fraction which decreased to 18 microg and 5 microg in the two subsequent 24 hourly fractions of urine. Exogenous supplementation of AsA increased the total urinary elimination of 3-BBA by almost 77%. A total of 10 fluorescent metabolites excluding the parent compound were eliminated in the urine of guinea pigs treated with 3-BBA. Densitometric scanning of chromatogram showed different peaks at Rf 0.18, 0.22, 0.27, 0.34, 0.40, 0.48, 0.56, 0.66, 0.72, 0.80, and 0.95 which were eliminated and marked as urinary metabolite 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 respectively. AsA not only significantly enhanced the elimination of 3-BBA metabolites but also modified the pattern of metabolites drastically in 0-6 h, 6-24 h and 24-48 h urine fractions.
CONCLUSIONThese results indicate that AsA may be useful in protecting the toxicity of 3-BBA by fascilitating the urinary metabolite(s) excretion of 3-BBA.
Administration, Oral ; Animals ; Antioxidants ; pharmacology ; Ascorbic Acid ; pharmacology ; urine ; Benz(a)Anthracenes ; analysis ; metabolism ; Chromatography, High Pressure Liquid ; Guinea Pigs ; Lipid Peroxidation ; drug effects ; Plant Oils ; metabolism ; Time Factors
2.Impact of Lysophosphatidylcholine on the Plasminogen Activator System in Cultured Vascular Smooth Muscle Cells.
Byung Koo YOON ; Young Hee KANG ; Won Jong OH ; Kyungwon PARK ; Dong Yun LEE ; Dooseok CHOI ; Duk Kyung KIM ; Youngjoo LEE ; Mee Ra RHYU
Journal of Korean Medical Science 2012;27(7):803-810
The balance between tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) regulates fibrinolysis. PAI-1 expression increases in atherosclerotic arteries and vascular smooth muscle cells (VSMCs) are one of major constituents of atheroma. We investigated the impact of lysophosphatidylcholine (lysoPC), an active component of oxidized low-density lipoprotein, on the plasminogen activator system of the rat VSMCs. The lysoPC stimulated the protein and gene expressions of PAI-1 but did not affect the protein expression of t-PA. Fibrin overlay zymography revealed that lysoPC increased the activity of PAI-1 in the conditioned media, while concurrently decreasing that of free t-PA. Vitamin E inhibited the lysoPC-induced PAI-1 expression. Further, lysoPC increased the intracellular reactive oxygen species (ROS) formation. Caffeic acid phenethyl ester, an inhibitor of NF-kappaB, blocked this lysoPC effect. Indeed, lysoPC induced the NF-kappaB-mediated transcriptional activity as measured by luciferase reporter assay. In addition, genistein, an inhibitor of protein-tyrosine kinase (PTK), diminished the lysoPC effect, while 7,12-dimethylbenz[a]anthracene, a stimulator of PTK, stimulated PAI-1 production. In conclusion, lysoPC does not affect t-PA expression but induces PAI-1 expression in the VSMC by mediating NF-kappaB and the genistein-sensitive PTK signaling pathways via oxidative stress. Importantly, lysoPC stimulates the enzyme activity of PAI-1 and suppresses that of t-PA.
Animals
;
Benz(a)Anthracenes/pharmacology
;
Caffeic Acids/pharmacology
;
Cells, Cultured
;
Genistein/pharmacology
;
Lipoproteins, LDL/metabolism
;
Lysophosphatidylcholines/*pharmacology
;
Muscle, Smooth, Vascular/cytology/*drug effects/metabolism
;
NF-kappa B/antagonists & inhibitors/metabolism
;
Oxidative Stress/drug effects
;
Phenylethyl Alcohol/analogs & derivatives/pharmacology
;
Plasminogen Activator Inhibitor 1/agonists/genetics/*metabolism
;
Protein Kinase Inhibitors/pharmacology
;
Protein-Tyrosine Kinases/antagonists & inhibitors/metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Reactive Oxygen Species/metabolism
;
Signal Transduction/drug effects
;
Tissue Plasminogen Activator/*metabolism
;
Transcription, Genetic/drug effects
;
Up-Regulation/drug effects
;
Vitamin E/pharmacology